Insight Molecular Diagnostics Inc. Total Liabilities
Insight Molecular Diagnostics Inc. total liabilities. Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has total liabilities worth $50.74 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IMDX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Insight Molecular Diagnostics Inc. (2013–2025)
Total liabilities of Insight Molecular Diagnostics Inc. from 2013 to 2025. This chart illustrates how Insight Molecular Diagnostics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Insight Molecular Diagnostics Inc. Competitors by Total Liabilities
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Enterprise Group Inc
TO:E
|
Canada | CA$39.38 Million |
|
NanoenTekInc
KQ:039860
|
Korea | ₩5.42 Billion |
|
Hana Pharm Co Ltd
KO:293480
|
Korea | ₩114.94 Billion |
|
Source Energy Services Ltd
TO:SHLE
|
Canada | CA$387.55 Million |
|
Patagonia Gold Corp
V:PGDC
|
Canada | CA$74.97 Million |
|
Pearson PLC
LSE:PSON
|
UK | GBX2.79 Billion |
|
Meridia Real Estate III Socimi SA
MC:YMRE
|
Spain | €68.49 Million |
|
Kewaunee Scientific Corporation
NASDAQ:KEQU
|
USA | $98.58 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Insight Molecular Diagnostics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Insight Molecular Diagnostics Inc..
Liquidity & Leverage Metrics
Insight Molecular Diagnostics Inc. Total Liabilities Ratios Explained
Insight Molecular Diagnostics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Insight Molecular Diagnostics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Insight Molecular Diagnostics Inc. (2013–2025)
The table below shows the annual total liabilities of Insight Molecular Diagnostics Inc. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $57.22 Million | +20.83% |
| 2024-12-31 | $47.35 Million | -12.99% |
| 2023-12-31 | $54.42 Million | -10.04% |
| 2022-12-31 | $60.50 Million | -35.88% |
| 2021-12-31 | $94.35 Million | +330.10% |
| 2020-12-31 | $21.94 Million | +143.17% |
| 2019-12-31 | $9.02 Million | +48.01% |
| 2018-12-31 | $6.09 Million | +4.85% |
| 2017-12-31 | $5.81 Million | +26.78% |
| 2016-12-31 | $4.58 Million | +98.14% |
| 2015-12-31 | $2.31 Million | -68.86% |
| 2014-12-31 | $7.43 Million | +59.03% |
| 2013-12-31 | $4.67 Million | -- |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more